UCB (OTCMKTS:UCBJY) Share Price Crosses Above 50 Day Moving Average – What’s Next?

UCB SA (OTCMKTS:UCBJY)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $137.71 and traded as high as $141.49. UCB shares last traded at $141.1670, with a volume of 32,273 shares traded.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on UCBJY. Jefferies Financial Group raised shares of UCB to a “moderate sell” rating in a research report on Sunday, October 26th. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy”.

UCB Stock Performance

The stock’s 50-day moving average price is $137.71 and its 200-day moving average price is $120.19.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.